Akari Therapeutics PLC (AKTX) - Total Liabilities
Based on the latest financial reports, Akari Therapeutics PLC (AKTX) has total liabilities worth $19.56 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore AKTX shareholders equity momentum to track the company's year-over-year net asset growth rate.
Akari Therapeutics PLC - Total Liabilities Trend (2010–2025)
This chart illustrates how Akari Therapeutics PLC's total liabilities have evolved over time, based on quarterly financial data. See AKTX cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Akari Therapeutics PLC Competitors by Total Liabilities
The table below lists competitors of Akari Therapeutics PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Siamraj Public Company Limited
BK:SR
|
Thailand | ฿1.25 Billion |
|
Manhattan Corporation Limited
F:32U
|
Germany | €230.23K |
|
Yoshiharu Global Co.
NASDAQ:YOSH
|
USA | $14.38 Million |
|
JE Cleantech Holdings Ltd
NASDAQ:JCSE
|
USA | $13.31 Million |
|
Pacific Nickel Mines Ltd
AU:PNM
|
Australia | AU$59.71 Million |
|
Garibaldi Resources Corp.
V:GGI
|
Canada | CA$3.63 Million |
|
Tyranna Resources Ltd
AU:TYX
|
Australia | AU$138.07K |
|
Protektor S.A.
WAR:PRT
|
Poland | zł39.39 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Akari Therapeutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Akari Therapeutics PLC (AKTX) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Akari Therapeutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Akari Therapeutics PLC (2010–2025)
The table below shows the annual total liabilities of Akari Therapeutics PLC from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $19.56 Million | -30.95% |
| 2024-12-31 | $28.33 Million | +518.08% |
| 2023-12-31 | $4.58 Million | -61.93% |
| 2022-12-31 | $12.04 Million | +97.61% |
| 2021-12-31 | $6.09 Million | +16.72% |
| 2020-12-31 | $5.22 Million | -19.32% |
| 2019-12-31 | $6.47 Million | +110.37% |
| 2018-12-31 | $3.08 Million | -66.09% |
| 2017-12-31 | $9.07 Million | -22.94% |
| 2016-12-31 | $11.77 Million | -44.41% |
| 2015-12-31 | $21.17 Million | +1201.42% |
| 2014-12-31 | $1.63 Million | -19.38% |
| 2013-12-31 | $2.02 Million | -54.96% |
| 2012-12-31 | $4.48 Million | +78.34% |
| 2011-12-31 | $2.51 Million | +21.76% |
| 2010-12-31 | $2.06 Million | -- |
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat s… Read more